Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.

Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia. Future Oncol. 2014 May; 10(7):1147-55.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.